Treatment of Severe Aplastic Anemia with Porcine Anti-Human Lymphocyte Globulin

Qi Lv; Zhang Huiqin; Xiao Na; Liu Chunyan; Shao Zonghong; Wang Huaquan

doi:10.2174/1381612826666200317131940

Treatment of Severe Aplastic Anemia with Porcine Anti-Human Lymphocyte Globulin

Curr Pharm Des. 2020;26(22):2661-2667. doi: 10.2174/1381612826666200317131940.

Authors

Qi Lv¹, Zhang Huiqin¹, Xiao Na¹, Liu Chunyan¹, Shao Zonghong¹, Wang Huaquan¹

Affiliation

¹ Department of Hematology, General Hospital, Tianjin Medical University, Tianjin 300052, China.

PMID: 32183661
DOI: 10.2174/1381612826666200317131940

Abstract

Aplastic anemia (AA) is a bone marrow failure syndrome characterized by pancytopenia. Decreased numbers of hematopoietic stem cells and impaired bone marrow microenvironment caused by abnormal immune function describe the major pathogenesis of AA. Hematopoietic stem cell transplantation and immunesuppressive therapy are the first-line treatments for AA. Porcine anti-lymphocyte globulin (p-ALG) is a new product developed in China. Several studies have shown that p-ALG exhibited good therapeutic effects in AA.

Keywords: Anemia; aplastic; hematopoietic; immunosuppressive; porcine anti-human lymphocyte globulin; treatment.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Anemia, Aplastic* / drug therapy
Animals
Globulins*
Hematopoietic Stem Cell Transplantation*
Hematopoietic Stem Cells
Immunosuppressive Agents
Lymphocytes
Swine

Substances

Globulins
Immunosuppressive Agents